STTK - NASDAQ

Shattuck Labs, Inc.

STTK·NASDAQ

$4.80

-1.4%

HealthcareBiotechnology

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$229.94M

EPS-0.7000

P/E Ratio-6.86

Earnings Date08/06/2026

sttk

Retained Earnings

Last Annual Value

-430.53M

3-Year CAGR

-25%

5-Year CAGR

-43%

10-Year CAGR

-44%

Adjust for Inflation

Shattuck Labs, Inc. Competitors Analysis of Retained Earnings

STTK · NASDAQ

Company	Retained Earnings	CAGR 3Y	CAGR 5Y	CAGR 10Y
Shattuck Labs, Inc. NASDAQ:STTK	-430.53M	N/A	N/A	N/A
ImageneBio Inc NASDAQ:IMA	-230.05M	N/A	N/A	N/A
Adverum Biotechnologies, Inc. NASDAQ:ADVM	-1.07B	N/A	N/A	N/A
ALX Oncology Holdings Inc. NASDAQ:ALXO	-722.82M	N/A	N/A	N/A
Spruce Biosciences, Inc. NASDAQ:SPRB	-289.23M	N/A	N/A	N/A
Unicycive Therapeutics, Inc. NASDAQ:UNCY	-127.83M	N/A	N/A	N/A
Pliant Therapeutics, Inc. NASDAQ:PLRX	-859.40M	N/A	N/A	N/A
Whitehawk Therapeutics Inc NASDAQ:WHWK	-353.25M	N/A	N/A	N/A
Metagenomi, Inc. Common Stock NASDAQ:MGX	-310.87M	N/A	N/A	N/A
Ovid Therapeutics Inc. NASDAQ:OVID	-321.71M	N/A	N/A	N/A
Kalaris Therapeutics Inc NASDAQ:KLRS	-160.00M	N/A	N/A	N/A

Shattuck Labs, Inc. Fair Value Envelope

STTK · NASDAQ

Our analysis suggests that STTK has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.8, this represents a potential HIDDEN relative to our calculated worth for Shattuck Labs, Inc..

HIDDEN

Intrinsic Value

Current Price: $4.8

Related Guides

Blog Categories

Continue your STTK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.